There is no problem with AZ vaccine safety

Domestic vaccines are aimed at development in the first half of next year

Domestic vaccine R&D is supported until the end, such as review of comparative clinical trials

The government announced that it is concerned about the avoidance of the AstraZenega (AZ) COVID-19 vaccine due to the thrombosis side effect issue.

 

It is said that there are no safety issues with side effects and solutions that appear around the world.

 

Son Young-rae, Team Leader of Countermeasure Headquarters COVID-19 Social Strategy, answered this way through Q&A for regular briefings in the morning of today (28th).

 

He said, "Recently, the amount of COVID-19 vaccine secured by purchasing additional Pfizer vaccines has increased to a total of 99 million this year.

 

As the supply of vaccines from other companies is increasing, we are concerned about the phenomenon of avoiding AZ vaccination." He said, "In the case of the UK, half of the vaccination targets are AZ products.

 

tens of millions of people are inoculated, so our government continues to monitor it." He said, "There is no problem with safety and rare thrombosis, which appears as a side effect, is also extremely rare, and because it is possible to treat it, the practical benefit of vaccination is high, so the Korean government also recommends vaccination." “Experts are also recommending AZ vaccination in common, and the Central Disaster Management Headquarters and the Central Disease Control Headquarters (employees) are also vaccinating AZ products.

 

I hope that the people do not worry more than necessary, and that the AZ product candidates receive the vaccine as much as possible." The authorities forecast the completion of domestic vaccine development in the first half of next year.

 

Five pharmaceutical companies have entered clinical trials through vaccine development, and it is expected to enter phase 3 as soon as possible in the second half of this year.

 

He said, "It is the principle that domestic vaccines are supported until they are successful, and the government is actively supporting them with the aim of developing them in the first half of next year.

 

It is difficult to recruit subjects due to the small number of domestic patients, but we will also review and apply for comparative clinical trials."